Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity

Journal of Molecular Biology

Volumn 315, Issue 3, 2002, Pages 339-350

  Kapurniotu, Aphrodite ^a   Schmauder, Anke ^a   Tenidis, Konstantinos ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Amyloid; Cytotoxicity; Inhibitor of amyloidogenesis; Islet amyloid polypeptide; sheet

Indexed keywords

AMIDE; AMYLOID; CONGO RED; CYTOTOXIC AGENT; DIMER; POLYMER; POLYPEPTIDE; PROTEIN IAPP; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; CELL VIABILITY; CHEMICAL REACTION; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; HYDROGEN BOND; INFRARED SPECTROSCOPY; METHYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; STAINING; VALIDATION PROCESS;

EID: 0036300750     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2001.5244     Document Type: Article

References (68)

1. Amyloidosis
2. Amyloid fibrillogenesis: Themes and variations
3. Deadly conformations-protein misfolding in prion disease
4. Progressive decline of β-cell function in non-insulin dependent diabetes
5. Configuration of polypeptide chains with favored orientation around single bonds: Two new pleated sheets
6. The structure of amyloid fibrils by electron microscopy and X-ray diffraction
7. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
8. Alternative conformations of amyloidogenic proteins govern their behavior
9. The toxicity in vitro of β-amyloid protein
10. β-Amyloid neurotoxicity requires fibril formation and is inhibited by congo red
11. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
12. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties
13. Neurotoxicity of a prion protein fragment
14. 1-42 are potent central nervous system neurotoxins
15. Inhibition of amyloid formation: A strategy to delay the onset of Alzheimer's disease
16. For protein misassembly it's the "I" decade
17. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization
18. β-Sheet breaker peptides inhibit fibrillogenesis in rat brain model of amyloidosis: Implications for Alzheimer's therapy
19. A strategy for designing inhibitors of β-amyloid toxicity
20. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide
21. Inhibition of toxicity in the β-amyloid peptide fragment β-(25-35) using N-methylated derivatives
22. Controlling amyloid β-peptide fibril formation with protease-stable ligands
23. Inhibition of β-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library
24. Amylin's pramlintide best of bad bunch of diabetes drugs
25. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type II diabetes
26. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients
27. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells
28. Pancreatic islet amyloid formation in patients with non-insulin-dependent diabetes mellitus
29. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: A peptide superfamily
30. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro
31. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles
32. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide
33. Neurotoxicity of human amylin to rat primary hippocampal cultures: Similarity to Alzheimer's disease amyloid β-neurotoxicity
34. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides
35. Seeding one-dimensional crystallization of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
36. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins
37. 1H NMR solution structure of an active monomeric interleukin-8
38. Conformational energy studies on N-methylated analogs of thyrotropin releasing hormone, enkephalin, and luteinizing hormone-releasing hormone
39. The nucleation of monomeric parallel β-sheet-like structures and their self-assambly in aqueous solution
40. N-methyl peptides. VII. Conformational perturbations induced by N-methylation of model dipeptides
41. On the stacking of β-rings: The solution self-association behavior of two partially N-methylated cyclo(hexaleucines)
42. Cylindrical β-sheet peptide assemblies
43. Protein misfolding, evolution and disease
44. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death
45. Rotational resonance solid-state NMR elucidates a structural model of pancreatic amyloid
46. The anatomy and taxonomy of protein structure
47. Effects of sequential proline substitutions on amyloid formation by human amylin(20-29)
48. Interspecies variations affect the kinetics and thermodynamics of amyloid plaque formation:peptide models of pancreatic amyloid
49. Selective amyloid staining as a function of amyloid composition and structure
50. Vibrational spectroscopy and conformation of peptides, polypeptides and proteins
51. The structural basis of pancreatic amyloid formation: Isotope-edited spectroscopy in the solid state
52. Circular dichroism of peptides
53. Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: A practical guide
54. Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism
55. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation
56. Konformation und biologische wirkung von cyclischen peptiden
57. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state
58. The role of prion peptide structure and aggregation in toxicity and membrane binding
59. Amylin
60. Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus
61. Inhibition of Alzheimer's amyloidosis by peptides that prevent ̈-sheet conformation
62. Structure-activity analyses of ̈-amyloid peptides: Contributions of the β25-35 region to aggregation and neurotoxicity
63. Modified-peptide inhibitors of amyloid β-peptide polymerization
64. Amyloid β-aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths
65. Arrest of β-amyloid fibril formation by a pentapeptide ligand
66. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides
67. Elements for the rational design of peptide drugs
68. Side reactions in peptide synthesis